Pacira BioSciences, Inc. (PCRX)

Market Cap	1.02B
Revenue (ttm)	716.79M
Net Income (ttm)	21.44M
Shares Out	43.02M
EPS (ttm)	0.47
PE Ratio	50.52
Forward PE	7.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	683,800
Open	23.32
Previous Close	23.17
Day's Range	23.14 - 24.18
52-Week Range	16.29 - 27.64
Beta	0.25
Analysts	Strong Buy
Price Target	33.83 (+42.08%)
Earnings Date	Nov 6, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Summary

According to 6 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price target is $33.83, which is an increase of 42.08% from the latest price.

Price Target

$33.83

(42.08% upside)

Analyst Consensus: Strong Buy